| scholarly article | Q13442814 |
| P50 | author | Hagop Kantarjian | Q60394812 |
| Stefan Faderl | Q64026412 | ||
| Srdan Verstovsek | Q64026418 | ||
| Gautam Borthakur | Q66370731 | ||
| Michael Andreeff | Q66385504 | ||
| Marina Konopleva | Q89564940 | ||
| Farhad Ravandi | Q40614280 | ||
| Jorge Eduardo Cortes | Q60320900 | ||
| P2093 | author name string | John J Wright | |
| Weiguo Zhang | |||
| Sheela Mathews | |||
| P2860 | cites work | Internal tandem duplication of the flt3 gene found in acute myeloid leukemia | Q71841108 |
| Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines | Q73501441 | ||
| Cell-surface exposure of phosphatidylserine correlates with the stage of fludarabine-induced apoptosis in chronic lymphocytic leukemia and expression of apoptosis-regulating genes | Q73645152 | ||
| Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia | Q27824808 | ||
| FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications | Q27851415 | ||
| Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia | Q27851423 | ||
| FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro | Q27851469 | ||
| Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation | Q28242368 | ||
| Raf kinase as a target for anticancer therapeutics | Q28244900 | ||
| Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia | Q28354257 | ||
| Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance | Q31832035 | ||
| Antitumor activity of sorafenib in FLT3-driven leukemic cells | Q33268279 | ||
| The roles of FLT3 in hematopoiesis and leukemia | Q34784925 | ||
| The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies. | Q35648838 | ||
| Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. | Q37234641 | ||
| Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis | Q39769534 | ||
| Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. | Q40024347 | ||
| BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. | Q40122807 | ||
| Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature | Q40270911 | ||
| Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain | Q40390558 | ||
| The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. | Q40399567 | ||
| Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia | Q40400934 | ||
| Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. | Q40459361 | ||
| The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia | Q40497248 | ||
| Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia | Q40543180 | ||
| In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects | Q40559231 | ||
| Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia | Q40571705 | ||
| A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response | Q42192063 | ||
| Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia | Q42742064 | ||
| A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study | Q43181954 | ||
| Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. | Q45042550 | ||
| Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors | Q46630294 | ||
| P433 | issue | 1 | |
| P921 | main subject | leukemia | Q29496 |
| patient | Q181600 | ||
| P304 | page(s) | 62-68 | |
| P577 | publication date | 2010-10-15 | |
| P1433 | published in | Haematologica | Q5638209 |
| P1476 | title | Phase I study of sorafenib in patients with refractory or relapsed acute leukemias | |
| P478 | volume | 96 |
| Q28072539 | 'Acute myeloid leukemia: a comprehensive review and 2016 update' |
| Q64125995 | A phase 2 study incorporating sorafenib into the chemotherapy for older adults with -mutated acute myeloid leukemia: CALGB 11001 |
| Q46931556 | A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. |
| Q101226635 | Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo |
| Q38644941 | Acute myeloid leukemia--major progress over four decades and glimpses into the future |
| Q37221579 | Acute myeloid leukemia: advancing clinical trials and promising therapeutics |
| Q30315977 | Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial |
| Q38168893 | Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update. |
| Q42376557 | An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia |
| Q41549311 | Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase |
| Q54109032 | Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. |
| Q37429734 | Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants |
| Q94686561 | Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms |
| Q46169481 | Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group |
| Q38848054 | Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia |
| Q27852520 | Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. |
| Q34004131 | Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia |
| Q35740894 | Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia |
| Q64250050 | Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia |
| Q91601798 | FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical? |
| Q38721796 | FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors |
| Q34993145 | FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia |
| Q36892604 | Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants |
| Q34647741 | Gene mutations and molecularly targeted therapies in acute myeloid leukemia. |
| Q90623570 | Gilteritinib: potent targeting of FLT3 mutations in AML |
| Q54517330 | High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. |
| Q40639927 | High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation. |
| Q37623389 | How I treat FLT3-mutated AML. |
| Q36270115 | Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review |
| Q38989349 | Inhibition of FLT3 in AML: a focus on sorafenib |
| Q43175180 | Inhibition of c-Kit by tyrosine kinase inhibitors |
| Q33943277 | Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia |
| Q36416358 | Is targeted therapy feasible in acute myelogenous leukemia? |
| Q41848868 | Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment |
| Q64075552 | Metabolic reprogramming and redox adaptation in sorafenib-resistant leukemia cells: detected by untargeted metabolomics and stable isotope tracing analysis |
| Q26749870 | Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy |
| Q35703167 | Monitoring chemotherapeutic response by hyperpolarized 13C-fumarate MRS and diffusion MRI. |
| Q38284045 | New treatment for acute myelogenous leukemia |
| Q64118224 | Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation? |
| Q89896286 | Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML |
| Q92814428 | Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers |
| Q53389797 | Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia. |
| Q36907832 | Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation |
| Q35172210 | Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia |
| Q35224437 | Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome |
| Q33401136 | Phase II study of sorafenib in patients with relapsed or refractory lymphoma. |
| Q33882022 | Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells |
| Q37399091 | Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study |
| Q49534332 | Precision therapy for acute myeloid leukemia |
| Q54160284 | Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. |
| Q36940606 | Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature |
| Q39016415 | Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies |
| Q64064165 | Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors |
| Q55487410 | Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib. |
| Q37865381 | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. |
| Q28087213 | Secondary mutations as mediators of resistance to targeted therapy in leukemia |
| Q33442949 | Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study |
| Q54113908 | Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship. |
| Q37663028 | Sorafenib Induced Hand Foot Skin Rash in FLT3 ITD Mutated Acute Myeloid Leukemia-A Case Report and Review of Literature |
| Q54235225 | Sorafenib and novel multikinase inhibitors in AML. |
| Q91813314 | Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party |
| Q45018784 | Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1. |
| Q34088370 | Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant |
| Q37213049 | Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells |
| Q37623535 | TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo |
| Q47965108 | Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199. |
| Q33903030 | Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia |
| Q61815346 | Targeting FLT3 mutations in AML: review of current knowledge and evidence |
| Q36352506 | Targeting oncogenic Ras signaling in hematologic malignancies |
| Q37644854 | Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia |
| Q36410157 | Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. |
| Q43089875 | The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML). |
| Q36693252 | The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations |
| Q34555386 | The Future of Targeting FLT3 Activation in AML. |
| Q38144189 | The role of quizartinib in the treatment of acute myeloid leukemia |
| Q36366626 | The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status |
| Q98243203 | Treating acute myeloid leukemia in the modern era: A primer |
| Q33772438 | Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib |
| Q39175665 | Treatment of Relapsed/Refractory Acute Myeloid Leukemia |
| Q47741553 | Treatment of relapsed/refractory acute myeloid leukaemia in adults |
| Q34011740 | Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations |
| Q89933301 | [Efficacy and safety of Sorafenib as monotherapy to FLT3-ITD positive acute myeloid leukemia] |
| Q53255166 | [Sorafenib in combination with chemotherapy as first-line therapy for FLT3-ITD positive acute myeloid leukemia]. |
| Q35485832 | p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12. |
Search more.